Xencor (XNCR) Research & Development (2013 - 2026)
Xencor's (XNCR) quarterly Research & Development came in at $64.7 million in Q1 2026, up 10.4% year-on-year from $58.6 million in Q1 2025, and little changed on a QoQ basis from $64.8 million in Q4 2025.
Xencor (XNCR) Research & Development (2013 - 2026) Analysis & Trends
Xencor (XNCR) has 14 years of Research & Development data on file, last reported at $64.7 million in Q1 2026.
- On a quarterly basis, Research & Development rose 10.4% year-over-year to $64.7 million in Q1 2026; TTM through Mar 2026 was $245.5 million, a 7.03% increase from a year earlier, with the FY2025 full-year figure at $239.4 million, up 5.16% from the prior year.
- Research & Development for Q1 2026 stood at $64.7 million, roughly flat from $64.8 million in the prior quarter.
- Over the last five years, Research & Development for XNCR reached as high as $64.9 million in Q3 2023 and fell as low as $47.1 million in Q2 2022.
- Historically, Research & Development has averaged $57.9 million across 5 years, with a median of $58.6 million in 2025.
- Across the five-year window, Research & Development surged 34.81% in 2023 and decreased 20.5% in 2024, its largest moves.
- Year by year, Research & Development stood at $51.5 million in 2022, then climbed by 24.82% to $64.2 million in 2023, then decreased by 20.5% to $51.1 million in 2024, then increased by 26.97% to $64.8 million in 2025, then dropped by 0.24% to $64.7 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $64.7 million in Q1 2026, $64.8 million in Q4 2025, and $54.4 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -17.94 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 541.22 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -2.31 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 961.60 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 1.54 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 15.66 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.37 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 343.97 Mn |
| 10 | Xencor | 1.47 Bn | 1.09 Bn | - | 64.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64.67 Mn |
| Dec 31, 2025 | 64.82 Mn |
| Sep 30, 2025 | 54.37 Mn |
| Jun 30, 2025 | 61.67 Mn |
| Mar 31, 2025 | 58.58 Mn |
| Dec 31, 2024 | 51.06 Mn |
| Sep 30, 2024 | 58.23 Mn |
| Jun 30, 2024 | 61.53 Mn |
| Mar 31, 2024 | 56.87 Mn |
| Dec 31, 2023 | 64.22 Mn |
| Sep 30, 2023 | 64.94 Mn |
| Jun 30, 2023 | 60.06 Mn |
| Mar 31, 2023 | 64.38 Mn |
| Dec 31, 2022 | 51.45 Mn |
| Sep 30, 2022 | 53.27 Mn |
| Jun 30, 2022 | 47.08 Mn |
| Mar 31, 2022 | 47.76 Mn |
| Dec 31, 2021 | 50.99 Mn |
| Sep 30, 2021 | 50.61 Mn |
| Jun 30, 2021 | 49.50 Mn |